SCHEMBL6553090

SCHEMBL6553090

CC[SiH](C=Cc1ccccc1)CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.44
RELA Q04206 2/20 0.44
CHAT P28329 2/20 0.40
NPC1 O15118 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTR2A P28223 3/20 0.39
TRPA1 O75762 1/20 0.39
GLA P06280 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GRM5 P41594 2/20 0.38
RAB9A P51151 1/20 0.38
GRM4 Q14833 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL886948 0.78 NPC1 (0.42) MAOBRELACHATNPC1L3MBTL1
SCHEMBL6114582 0.78 RELA (0.41) MAOBRELACHATNPC1L3MBTL1
SCHEMBL15302240 0.78 RELA (0.41) MAOBRELACHATNPC1L3MBTL1
SCHEMBL886947 0.78 NPC1 (0.42) MAOBRELACHATNPC1L3MBTL1
SCHEMBL15864842 0.76 RELA (0.38) MAOBRELANPC1L3MBTL1HTR2A
SCHEMBL886959 0.75 RELA (0.43) MAOBRELANPC1L3MBTL1TRPA1
SCHEMBL886960 0.75 RELA (0.43) MAOBRELANPC1L3MBTL1TRPA1
SCHEMBL304129 0.74 MAOB (0.46) MAOBRELACHATNPC1TRPA1
SCHEMBL17210194 0.74 MAOB (0.46) MAOBRELACHATNPC1TRPA1
SCHEMBL886954 0.74 RELA (0.46) MAOBRELACHATNPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2620441-B1 MODIFIED PRODUCT OF POLYHEDRAL STRUCTURE POLYSILOXANE, POLYHEDRAL STRUCTURE POLYSILOXANE COMPOSITION, CURED PRODUCT, AND OPTICAL SEMICONDUCTOR DEVICE KANEKA CORP (JP) 2018-10-31 EP disclosed
US-9698320-B2 Modified product of polyhedral structure polysiloxane, polyhedral structure polysiloxane composition, cured product, and optical semiconductor device KANEKA CORPORATION (JP) 2017-07-04 US disclosed
US-20130237663-A1 MODIFIED PRODUCT OF POLYHEDRAL STRUCTURE POLYSILOXANE, POLYHEDRAL STRUCTURE POLYSILOXANE COMPOSITION, CURED PRODUCT, AND OPTICAL SEMICONDUCTOR DEVICE KANEKA CORPORATION (JP) 2013-09-12 US disclosed
EP-2620441-A1 MODIFIED PRODUCT OF POLYHEDRAL STRUCTURE POLYSILOXANE, POLYHEDRAL STRUCTURE POLYSILOXANE COMPOSITION, CURED PRODUCT, AND OPTICAL SEMICONDUCTOR DEVICE Kaneka Corporation (JP) 2013-07-31 EP disclosed
US-20040186104-A1 Novel pyridinone and related heterocyclic derivatives ASTRAZENECA AB (SE) 2004-09-23 US disclosed
EP-1387829-A1 NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES AstraZeneca AB (SE) 2004-02-11 EP disclosed
WO-2002090333-A1 NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237663-A1 MODIFIED PRODUCT OF POLYHEDRAL STRUCTURE POLYSILOXANE, POLYHEDRAL STRUCTURE POLYSILOXANE COMPOSITION, CURED PRODUCT, AND OPTICAL SEMICONDUCTOR DEVICE HSF1, PIEZO1, HSP90AA1 MAOB 4240/4885RELA 2407/4885CHAT 4757/4885
US-20040186104-A1 Novel pyridinone and related heterocyclic derivatives CBR1, CBR3, CHRM1 MAOB 310/4885RELA 816/4885CHAT 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.